07:00 , Aug 10, 2009 |  BioCentury  |  Regulation

PEGging Krystexxa

Following a positive panel review in June, Savient Pharmaceuticals Inc. expected to spend the week leading up to its Aug. 1 PDUFA date finalizing the launch of its Krystexxa pegloticase for chronic refractory gout candidate....
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

Foamix management update

Foamix Ltd. , Ness Ziona, Israel   Business: Drug delivery   Hired: David Schuz as SVP of IP, formerly VP of legal at Bio-Technology General (Israel) Ltd.  ...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

Savient drug delivery, metabolic news

SVNT plans to divest its Israeli operations, including subsidiary Bio-Technology General Ltd. (Rehovot, Israel), to focus on development of prosaptide for peripheral neuropathic pain and Puricase pegylated urate oxidase for severe refractory gout. Prosaptide is...
07:00 , Oct 6, 2003 |  BC Week In Review  |  Company News

Savient, Teva deal

Specialty pharma company SVNT said it is in talks to be acquired by TEVA for a cash sum that approximates SVNT's Oct. 2 close of $6.14. This would value SVNT (formerly Bio-Technology General) at $365.3...
07:00 , Oct 3, 2003 |  BC Extra  |  Company News

Savient, Teva in acquisition talks

Specialty pharma company SVNT said it is in talks to be acquired by TEVA for a cash sum that "approximates" SVNT's Thursday close price of $6.14. This would value SVNT (formerly Bio-Technology General ) at...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Company News

Savient management update

Savient Pharmaceuticals Inc. (SVNT), East Brunswick, N.J.   Business: Drug delivery, Metabolic   Promoted: Dov Kanner to EVP and CTO from SVP, while remaining managing director of SVNT’s Bio-Technology General (Israel) Ltd. subsidiary  ...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Company News

Bio-Technology General board of directors update

Bio-Technology General Corp. (BTGC), East Brunswick, N.J.   Business: Drug delivery, Metabolic   Appointed: Jeremy Hayward-Surry, retiring president of Pall Corp. ; and Stephen Jaeger, president, chairman and CEO of eBT International Inc.   Retired:...
08:00 , Mar 31, 2003 |  BC Week In Review  |  Company News

Bio-Technology General management update

Bio-Technology General Corp. (BTGC), East Brunswick, N.J.   Business: Drug delivery, Metabolic   Hired: Zeb Horowitz as SVP and CMO, formerly executive director and global head of arthritis and bone research at Novartis AG 's...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Company News

Bio-Technology General management update

Bio-Technology General Corp. (BTGC), Iselin, N.J.   Business: Metabolic, Ophthalmic   Promoted: Robert Shaw to EVP and chief administrative officer, while remaining general counsel and secretary; and Andre Groenewegen to SVP, while remaining managing director...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Company News

Antares, Bio-Technology General, Ferring Pharmaceuticals deal

The companies ended a 1999 deal under which BTGC received exclusive rights to ANTR's needle-free injector technology for the U.S. human growth hormone market. As ended, ANTR reacquired rights for the indication. Separately, ANTR and...